Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

First Tracks Biotherapeutics Inc

TRAX · NASDAQ · USD · Market cap $1.7B · 104 employees

First Tracks Biotherapeutics, Inc.

FAIL · Does not pass the screen
41.64 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price41.64 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.00)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $57.00 to $83.28, base estimate $70.00 (screen dated 2026-11-20).

Current read
Accumulation ?
Undervalued · screened 2026-11-20
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.00, read 2026-11-20
  • Ethical does not pass the values gate
Price41.64 USD
Fair value70.00
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-01Read Accumulation45.08-7.6% to today Markup gives way to Accumulation
2026-10-29Read Markup43.48-4.2% to today Distribution gives way to Markup after a 27% rise in 4 days
2026-10-25Read Distribution34.13+22.0% to today Markdown gives way to Distribution after a 20% slide in 6 weeks
2026-09-11Read Markdown42.51-2.0% to today ✓Markup gives way to Markdown after a 16% rise in 4 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

First Tracks Biotherapeutics Inc holds its Accumulation at $41.64. The statistical read favours the sellers, held for 69 days.

As held on the ledger · 2026-11-20
PhaseAccumulation
Quantitative stateThe statistical read favours the sellers, held for 69 days
Price at the screen$41.64
ValuationN/A trailing · -12.03 forward price to earnings
Values screenFAIL · score 70.0
The Workings

Five Screens: TRAX's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 3.63% Below 33% Pass
Interest-bearing cash 59.36% Below 33% Fail
Receivables 27.85% Below 49% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

First Tracks Biotherapeutics's business is fine, but its cash and interest-bearing securities are about 59% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when TRAX's ethical verdict changes

Today TRAX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 41% discount to our $70.00 fair value.

Method.

57.00Conservative70.00Base case83.28Growth case 41.64Price

USD, 2026-11-20 screen. A 40.5% under base.

The Street's Range
57.00Street low 70.00Street average 110.00Street high 41.64Price

Street: 12 covering, consensus Strong Buy. Average target +68%.

Chart
The Business, in Plain Words

Early Biotech Still Waiting On First Proof

Picture a lab bench with one promising molecule and no sales yet. First Tracks is exactly that, a clinical stage player whose lead candidate targets autoimmune inflammation but has delivered zero revenue and zero profit margin so far. The negative forward earnings multiple simply reflects cash burn that every similar name carries until trials clear later stages.

We pass because the opportunity rating shows none. An unknown moat, no current earnings, and heavy dependence on a single unproven asset outweigh the 15 percent gap to our fair value and the analysts' strong buy chorus. Ethical clearance is welcome, yet it does not turn an incomplete story into an investable one.

The real risk sits in trial failure or dilution that resets the clock, a pattern common in this sector. Peak earnings are nowhere in sight, so the low multiple offers no bargain, only a reminder that hope is not a margin. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-12.0x
EPS, trailing-4.71
EPS, forward-3.46
Profit margin0.0%currently unprofitable
Debt to equity2.50heavy leverage: higher risk if revenue softens
Current ratio9.16comfortably covers its short-term bills
52-week range14.72 - 54.78
Market cap$1.7B
Employees104

TRAX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Accumulation $44.50 +0.0% Entry 16
2026-11-19 Accumulation $44.50 -11.9% Entry 15
2026-11-12 Accumulation $50.53 +3.0% Entry 14
2026-11-05 Accumulation $49.04 +5.8% Entry 13
2026-11-04 Accumulation $46.34 +2.8% Entry 12
2026-11-03 Accumulation $45.08 +0.0% Entry 11
2026-11-02 Accumulation $45.08 +0.0% Entry 10
2026-11-01 Accumulation · changed $45.08 +3.7% Entry 9

The framework has shifted from markup to accumulation since the last review.

2026-10-31 Markup $43.48 +0.0% Entry 8
2026-10-30 Markup $43.48 +0.0% Entry 7

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on TRAX

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in TRAX's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $18.76 -12.5% · $875 -12.5%
2 months $23.50 -30.1% · $699 -30.1%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever TRAX does next, these words stay.

First Tracks Biotherapeutics Inc · TRAX · Accumulation · $41.64
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.